NIPH Clinical Trials Search

JRCT ID: jRCTs062220031

Registered date:09/06/2022

Dual-wield parenchymal transection for liver resection using Cavitron Ultrasonic Surgical Aspirator and water-jet scalpel

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedLiver tumor
Date of first enrollment24/06/2022
Target sample size20
Countries of recruitment
Study typeInterventional
Intervention(s)In current liver surgery, transection of liver parenchymal is performed by two surgeons using CUSA and bipolar. In this study, in addition to CUSA and bipolar, water-jet scalpel is used simultaneously by another surgeonf for liver parenchymal transection.


Primary OutcomePercentage of cases with massive intraoperative bleeding (1000 ml or more)
Secondary Outcome1. Surgical factors (total operation time, time of liver parencymal transection, velocity of liver parencymal transection, time of liver inflow occlusion, number of liver inflow occulusion, intraoperative bleeding) 2. Short-term postoperative outcome (incidence of all postoperative complications based on Clavien-Dindo classification, incidence of post-hepatectomy liver failure and bile fistula based on the ISGLS definition, surgical mortality, post-operative stay)

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
Include criteria1. Patients who undergo anatomical liver resection for primary or metastastic liver tumor. 2. Patients with Performance Status (PS) 0-1 of Eastern Cooperative Oncology Group (ECOG). 3. Patients over 20 years old. 4. Patients without extrahepatic lesions. However, patients with extrahepatic lesions could be included if excision of intrahepatic lesion prolongs theirprognosis. 5. Patients who meet following criteria of blood examination. A) White blood cell cout: 2000/mm3 or more. B) Hemoglobin: 8.0 g/dL or more. C) Platelet count: 50,000/mm3 or more. D) Total bilirubin: 3.0 mg/dL or less. E) Prothrombin activity: 50 % or more. F) Creatinine: 2.0 mg/dL or less 6. Patients who understand the contents of this study.
Exclude criteria1. Patients who undergo liver resection with biliary duct reconstructon. 2. Patients who undergo liver resection witu revascularization. 3. Patients who undergo simultaneous surgery for other organ, exepting cholecystectomy. 4. Patients with severe ischemic heart disease (NYHA clasicifation grade III or IV). 5. Patients with severe cirrhosis (Liver damage grade C). 6. Patients required continuous oxygen administration due to severe lung disease. 7. Patiets with severe or uncontrollable coagulapathy. 8. Patients who receive treatment for active cancer of other organs. 9. Patietns who are lactating or pregnant. 10. Patients who are dfficult to enroll in this study due to their mental illness. 11. Patients who undergo dialysis. 12. Patients implanted with medical electronic devices such as pacemakers and implantable cardioverter-defibrillators. 13. Patients who are deemed inappropriate for this study by the investigator .

Related Information


Public contact
Name Tsuyoshi Kobayashi
Address 1-2-3 Kasumi, Minami-ku, Hiroshima, Hiroshima Hiroshima Japan 734-8551
Telephone +81-82-257-5222
Affiliation Hiroshima University Hospital
Scientific contact
Name Hideki Ohdan
Address 1-2-3 Kasumi, Minami-ku, Hiroshima, Hiroshima Hiroshima Japan 734-8551
Telephone +81-82-257-5222
Affiliation Hiroshima University Hospital